Dermaliq Therapeutics, Inc. is pioneering advancements in dermatology and aesthetics through its proprietary hyliQ® technology, which addresses the challenges of drug delivery in treating skin and hair disorders. This innovative platform enables the effective penetration of active ingredients into the skin and hair follicles, overcoming traditional barriers associated with topical treatments. By utilizing novel lipophilic excipients with low viscosity and surface tension, hyliQ® facilitates rapid absorption and the formation of active ingredient depots within the skin's glands. This targeted delivery system not only enhances the efficacy of treatments for conditions such as psoriasis, eczema, and alopecia but also minimizes the risk of systemic side effects, making it a significant advancement in dermatological care.

The company’s pipeline includes several promising drug candidates that leverage the hyliQ® technology. For instance, DLQ01 is a topical formulation aimed at treating androgenetic alopecia, showing impressive Phase 2 results with over 80% of subjects experiencing positive hair growth changes. Similarly, DLQ02 targets alopecia areata with a dual-action mechanism that combines immunomodulation and promotes hair growth, while DLQ03 focuses on accelerating wound healing and preventing secondary infections. These developments underscore Dermaliq's commitment to creating high-quality, user-friendly products that prioritize safety and effectiveness in treating a range of dermatological conditions.

United States

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology owned by Dermaliq, called hyliQ, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties.

Dermaliq Therapeutics

Company Details